Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
Why now
Thesis: At-the-market warrant inducement signals dilution for small-cap biotech
Catalyst to watch: Use of proceeds or subsequent financing terms
Main risk: Shareholder dilution pressure on the stock
Why it matters
Warrant inducement priced at-the-market typically signals dilution pressure for a small-cap biotech.
Details
HOUSTON, Sept. 22, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families,...
Sources
- prnewswire · 2026-09-22 16:50 UTC